Results of a Phase II Trial of Brentuximab Vedotin for CD30(+) Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis

PURPOSE: Brentuximab vedotin, a monoclonal antibody (cAC10) conjugated to monomethyl auristatin E, targets CD30(+) receptors. This phase II open-label trial was conducted to evaluate safety and efficacy in CD30(+) cutaneous T-cell lymphomas. PATIENTS AND METHODS: Forty-eight patients with CD30(+) ly...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Duvic, Madeleine, Tetzlaff, Michael T., Gangar, Pamela, Clos, Audra L., Sui, Dawen, Talpur, Rakhshandra
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2015
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4737859/
https://ncbi.nlm.nih.gov/pubmed/26261247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.3787
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker